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Background
Major advantages of perfusion are high cell numbers
and high total production in a relatively small size bior-
eactor. Moreover, perfusion is optimal when the product
of interest is unstable or if the product yield is low. On
the other hand, disadvantages are for example technical
challenges originating from non-robust cell separation
devices as well as sterility concerns from the more com-
plex set-up needed.
In the present work, the use of a WAVE Bioreactor™
system 20/50 in perfusion mode with10 L disposable
Cellbag™ bioreactors customized with two dip tubes in
combination with disposable hollow fiber filters as exter-
nal cell separating devices were investigated. A compari-
son between Alternating Tangential Flow (ATF) and
Tangential Flow Filtration (TFF) was performed using a
recombinant CHO cell line producing a monoclonal
antibody (mAb) as a model system.
Materials and methods
A research cell line DHFR
- CHO producing mAb was
used. During expansion cultures in shake flasks, MTX
selection pressure was performed but omitted in bior-
eactor. A WAVE Cellbag™ (10 L) containing two dip
tubes (GE Healthcare) at 4L working volume was con-
nected either to an ATF-2 device (Refine Technology,
USA) or to a ReadyToProcess™ filter (TFF) via a Wat-
son Marlow 620S pump. In both systems, the hollow
fiber filters (HF), RTPCFP-2-E-4X2MS, GE Healthcare,
Sweden, had 0.2 μm pore size, 1 mm lumen and 850
cm
2 filter area. The pressure rising flow (ATF), the
exhaust flow (ATF) and the recirculation flow rate
(TFF) were 0.7 or 1 L/min. The set-points of DO, pH
and temperature were 35 %, 7 and 37°C respectively.
The agitation rate was varied between 20-26 rpm, 6-7°
and 20-27 rpm, 6-8° for ATF and TFF respectively. O2
addition was performed in the headspace (20-100%) and
the DO control was operated by varying the agitation.
The cells were cultivated in serum-free, animal-com-
ponent free IS CHO CD XP medium (Irvine Scientific,
USA) with hydrolysate, supplemented with 3 % of IS-
CHO Feed-CD XP (Irvine Scientific, USA) and with 4
mM glutamine with a cell specific perfusion rate of 0.05
Reactor Volume/(day x 10
6 cells/mL). Supplementations
of glucose or glutamine were performed according to
cell need. The pH was controlled by adding 0.5 M
Na2CO3 or pulsing CO2 into the headspace. The cell
density, viability, pH, pCO2, concentrations of glucose,
lactate, glutamine and ammonia were measured by Bio-
profile FLEX (Nova Biomedical). Antifoam C (Sigma
Aldrich, US) was added up to 50 ppm concentration in
the bioreactor either by boost addition or by continuous
pumping. The mAb concentration was measured by
protein A HPLC.
Results
Cell density, viability and perfusion rate
Two perfusion experiments (ATF9 and ATF15) were
conducted using ATF (Figure 1A) and one perfusion
culture (TFF10) using TFF device (Figure 1B). In experi-
ments ATF9 and TFF10, cell density was maintained
between 20-30 x 10
6 cells/mL by daily cell bleeds for 2
weeks using one HF. Interestingly, in experiment ATF9,
the use of an ATF flow rate of 0.7 L/min was not suffi-
cient to remove bubbles entrapped in the HF resulting
in a decrease in viability (93.5% vs. 97%). Therefore,
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any medium, provided the original work is properly cited.from day 9, the flow rate was increased to 1 L/min, i.e.
shear stress of 3400 s
-1. Experiment ATF15 was per-
formed at 1 L/min.
In experiment ATF15, a cell density of 132 x 10
6 cells/
mL was reached after 10 days of culture of exponential
growth. Reaching this density coincided with interruption
of ATF function due to insufficient pressure to push the
highly viscous cell broth, showing the limit of this system
at this very high cell density when using a non-pressuri-
sable disposable bioreactor. A batch culture was then car-
ried out between days 13 and 20 (data not shown) after
which perfusion was re-started. A maximal cell density of
123 x 10
6 cells/mL was obtained confirming the first
observed maximal cell density. The culture was then con-
tinued for 4 days at cell density around 100 x 10
6 cells/
mL by performing daily cell bleeds showing that healthy
high cell density culture could be obtained somewhat
under 130 x 10
6 cells/mL in the same culture.
Using the TFF, exponential cell growth was obtained
at similar rate as with ATF, the cell density was then
maintained around 100 x 10
6 cells/mL by daily cell
bleeds for 2 weeks. Then, higher cell densities were
achieved, up to more than 200 x 10
6 cells/mL for 2
days. Reaching 214 x 10
6 cells/mL coincided with the
limit of this system due to high pressure in re-circula-
tion loop (1 bar) related to the viscosity, oxygenation
limitation and CO2 accumulation (31 kPa). During these
runs, CHO cells were cultivated at high and very high
cell densities with a cell viability maintained above 90%
(mostly around 95%).
Total mAb production
Over an 17-day period of culture with cell densities
maintained at 20-30 x 10
6 cells/mL, a total of 9 g and 7
g of mAb were harvested in the ATF9 and TFF10 pro-
cesses respectively (Table 1). The lower yield obtained
using the TFF was mainly due to mAb removed in cell
bleeds (30% in TFF vs. 19% in ATF). In both cultures,
the cell specific production rates of mAb were similar
and around 10-15 pg/cell/day (data not shown).
Figure 1 Viable cell density (●, ○), viability (▲, △)a n dp e r f u s i o nr a t e( ■, □) in perfusion processes using ATF system (A) and TFF system (B).
Closed symbols indicate the ATF9 perfusion experiment, whereas the open symbols represent the ATF15 and TFF10 perfusion experiments.
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A very high cell density of 100 x 10
6 cells/mL was stably
maintained in growing phase and at high viability by
performing cell bleeds in a perfused WAVE Bioreac-
tor™ using TFF or ATF cell separations. With the set-
tings used here, the maximal cell density was limited to
214 x 10
6 cells/mL using TTF and 132 x 10
6 cells/mL
using ATF. Using TFF, the cell density could not be
further increased due to the limitations of membrane
capacity (for the encountered high viscosity), oxygena-
tion and CO2 level, and using ATF due to pressure lim-
itation to push highly viscous fluid and use of non-
pressurisable disposable bioreactor. Thus, the TFF sys-
tem allowed reaching higher cell densities. To our
knowledge, it is the first time that a CHO cell density of
more than 200 x 10
6 cells/mL was achieved in a wave-
agitated bioreactor.
Higher retentions of mAb were observed using the
TFF system than using the ATF system. In perfusion,
the major effect of this retention was loss of mAb in the
cell bleeds. Consequently, ATF system was more favour-
able for production at stable cell density maintained by
cell bleeds.
T h eu s eo fad i s p o s a b l eb i o r e a c t o re q u i p p e dw i t ha
disposable separation device offers a solution alleviating
technical and sterility challenges occurring in perfusion
processes.
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Table 1 Comparison of mAb production using ATF or TFF
system at day 17 with cell densities maintained at 20-30
x1 0
6 cells/mL.
ATF TFF
Production in harvest (g) 97
Yield (production in harvest/total production) (g/g in %) 75 55
Total removal of mAb in cell bleeds/total production (g/g in
%)
19 30
Residual mAb mass in bioreactor/total production (g/g in %) 61 5
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